NCT01781429 - Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 28, 2018

Study Completion Date

September 30, 2018

Conditions

Advanced Solid Tumors

Interventions

DRUG

BVD-523

Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle

Trial Locations (9)

Memorial Sloan-Kettering Cancer Center, New York

Florida Cancer Specialists and Research Group (Sarah Cannon Research Institute), Sarasota

Sarah Cannon Research Institute Hospital at Vanderbilt, Nashville

Vanderbilt-Ingram Cancer Center, Nashville

Washington University School of Medicine, St Louis

UT M.D Anderson Cancer Center, Houston

UCLA Med-Hematology & Oncology, Los Angeles

Yale Cancer Center, New Haven

Massachusetts General Hospital (MGH), Boston